BioNovion, Aduro Biotech deal

Aduro will also gain BioNovion’s antibody production technology, which is based on the clonal expansion of cultured B cells isolated from the spleen or lymph nodes of immunized mice, and five bispecific antibodies against undisclosed immune-oncology targets generated under a March deal with Genmab A/S (CSE:GEN;OTCBB:GMXAY, Copenhagen, Denmark) and that use Genmab’s DuoBody Technology. ...